Finally a Cure for the Common Cold? And it’s Needle-free!

28/11/2016 - 2 minutes

Mucosis is starting Phase I trials for SynGEM, a needle-free vaccine against RSV, which causes 200k deaths per year and has a huge cost for both healthcare and the economy.

Mucosis is a biotech from the Netherlands developing needle-free vaccines. The company has now initiated the first human trial for SynGEM, a nasal spray vaccine against respiratory syncytial virus (RSV), one of the most common viruses causing common colds.

The Phase I trial is taking place at Imperial College London and supported with €3.4M from the UK’s Wellcome Trust. In it, 36 volunteers were administered the vaccine and will be tested for antibody production. Results are expected in early 2017, followed by a Phase II programmed for mid-2017.

Although colds are often regarded as harmless, infants and elderly people are at high risk of developing pneumonia, bronchiolitis and other severe complications. The number of deaths attributed to RSV amounts to up to 200,000 per year, while others suffering from the 64 million annual infections can be left severely weakened.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

You might also be interested in the following: